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Stability-indicating methodAbstract A stability-indicating LC method was developed and validated for the determination of
luliconazole in bulk and cream formulation. Luliconazole was exposed to acid, alkali and water
hydrolysis, oxidation effect by hydrogen peroxide, dry heat and photolytic conditions. Full factorial
design was used during forced degradation experiments and the factors/combination of factors
which were most likely to effect degradation of luliconazole under various conditions were identi-
ﬁed and further were optimized using surface response curve. Drug was found to be stable under
wet heat and dry heat conditions, but substantial degradation was observed under acid, alkali, oxi-
dative and photolytic conditions. Drug and its degradation products were optimally resolved on
HiQ sil C-18HS (250 · 4.6 mm, 5 lm) column with the mobile phase consisting of methanol and
water (80:20, v/v) at a ﬂow rate of 1 mL/min, detection was performed at 296 nm. The procedure
was validated for speciﬁcity, linearity, accuracy and precision. There was no interference of excip-
ients and degradation products in the determination of active pharmaceutical ingredient. The
method was accurate and precise and the response was found to be linear in the range of
2–14 lg/mL. The method was found to be simple and fast by making use of experimental design.
ª 2012 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Forced degradation/stress testing, deﬁned as the stability test-
ing of drug substance and drug product under conditions
exceeding those used for accelerated testing (Klick et al., 2005).
From a drug development and regulatory perspective,
forced degradation studies provide data for the identiﬁcation
of possible degradation products, prediction of degradation
pathway, validation of stability-indicating analytical
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less
stable, the choice of packing material and selection of storage
conditions (Alsante et al., 2007).
Although the regulatory guidance documents deﬁne the
concept of stress testing, they do not provide detailed informa-
tion about a stress testing strategy. The experimental condi-
tions to conduct stress testing are described in a general way
and the exact stress conditions to be applied are not described
(Bakshi et al., 2002). The available guidance documents also
do not state the extent to which stress tests should be carried
out (that is how much stress should be applied or how much
degradation should be aimed for).
To address the two issues – experimental design for forced
degradation and extent of forced degradation to be attempted,
researchers have suggested that degradation can be achieved
by exposing the drug, for extended periods of time, to extremes
of pH (aqueous, hydrochloric acid or sodium hydroxide solu-
tions) at elevated temperatures, to hydrogen peroxide at room
temperature or to UV light and to dry heat (in an oven) while
adopting trial and error approach to select the strength, tem-
perature and time of exposure to the stress conditions so as
to achieve degradation to an extent of 10–20%. (Singh and
Bakshi, 2000; Reynolds et al., 2000), actually, such trial and er-
ror approach are cost, time and labor intensive and should be
substituted by more systemic approach.
One such systemic approach is to adopt statistical nested
design like factorial design (Lundstedt et al., 1998; Morgan
et al., 1989; Leardi, 2009) to reveal the variables (strength, tem-
perature or time of exposure) which are most likely to inﬂuence
degradation and modify only these parameters to effect the
adequate degradation. The basic concept of factorial design
also addresses the interaction between two variables. This
can reveal the combination of variables (heat/pH, heat/time,
etc.), which could result in increased susceptibility of the drug
to degradation, thus giving valuable inputs toward the ulti-
mate choice of storage conditions. The present work directed
toward the use of factorial design to bring about forced degra-
dation under various stress conditions.
Luliconaozole (LCZ) was selected as a model drug for this
study. It is chemically, 4-(2,4-dichlorophenyl)-1,3-dithiolan-2-
ylidene-1-imidazolylacetonitrile, a novel antifungal drug
launched in India by Ranbaxy Laboratories Ltd. The com-
pound was originally screened from active compounds related
to lanoconazole, a potent antidermatophytic drug. LCZ pos-
sesses a wide spectrum of antifungal activity and is very potent
against dermatophytes (Uchida et al., 2004). Till date no ana-
lytical method was reported for quantitative estimation of
LCZ.
Thus, a simple and rapid stability-indicating liquid chro-
matographic method has been developed and validated for
LCZ.2. Experimental
2.1. Chemicals and reagents
The LCZ reference standard (RS) was kindly supplied by
Ranbaxy Laboratories Ltd. (Gurgaon, Haryana, India). The
cream formulation, LuliﬁnTM (Ranbaxy Laboratories Ltd.,
Gurgaon, Haryana, India) composed of 10 mg of LCZ in eachgram, was purchased in the market. All chemicals used were of
analytical grade and all solvents were of LC grade. Methanol
was purchased from SD Fine Chemicals (Mumbai, India).
The 0.45 lm pore Nylon ﬁlter papers were purchased from Pall
India Pvt. Ltd. (Mumbai, India).
2.2. HPLC instrumentation and conditions
HPLC system consisted of pump PU-2080 plus (JASCO
Corporation, Tokyo, Japan), with Rheodyne Loop Injector
(7725 i) ﬁtted with 20 lL sample loop. Detection was carried
out using UV-2075 detector (JASCO Corporation, Tokyo, Ja-
pan). The data acquisition was done using Borwin chromatog-
raphy software version 1.50. The HPLC column was a HiQsil
C18HS (250 mm · 4.6 mm i.d., 5 lm), Kya Technologies Cor-
poration, Tokyo, Japan. The chromatographic separation was
performed using mobile phase consisting of methanol and
water (80:20, v/v), with ﬂow rate of 1 mL/min. The detector
was set at 296 nm.
2.3. Forced degradation study by factorial design
LCZ was subjected to stress under acidic, alkaline, oxidative,
thermolytic and photolytic conditions. For acid, alkali, oxida-
tive, dry heat and wet heat conditions, values of variables like
time of exposure, temperature and strength were chosen so as
to obtain 10–20% degradation. This choice was facilitated by
the initial experiments as per the factorial design and perform-
ing multiple regression equation to identify conditions for de-
sired 10–20% degradation.
(a) Acid degradation: 1 mg/mL mixture of LCZ in X1 M
HCl was heated under reﬂux at X2 C for X3 min. Two
levels were chosen for each of X1, X2 and X3. The high
level (+1) for X1, X2 and X3 was 1 M, 75 min and
100 C, respectively, and the low level (1) for X1, X2
and X3 was 0.1 M, 15 min and 60 C, respectively. Since
three variables were considered at two levels, a 23 facto-
rial design was conducted to set up eight experiments.
(b) Alkali degradation: 1 mg/mL mixture of LCZ in X1 M
NaOH was heated under reﬂux at X2 C for X3 min.
Two levels were chosen for each of X1, X2 and X3. The
high level (+1) for X1, X2 and X3 was 0.1 M NaOH,
30 min and 100 C, respectively, and the low level (1)
for X1, X2 and X3 was 0.01 M, 10 min and 60 C, respec-
tively. Since three variables were considered at two lev-
els, a 23 factorial design was conducted to set up eight
experiments.
(c) Oxidative degradation: 1 mg/mL mixture of LCZ was
maintained in X1% H2O2 in dark for X2 min. Two
levels were chosen for X1 and X2. The high level
(+1) for X1 and X2 was 30% and 24 h, respectively,
and the low level (1) for X1 and X2 was 3% and
2 h, respectively. Since two variables were considered
at two levels, a 22 factorial design was conducted to
set up four experiments.
(d) Dry heat degradation: LCZ powder was spread as a thin
ﬁlm in petri plate and exposed to X1 C for X2 min. Two
levels were chosen for X1 and X2. The high level (+1) for
X1 and X2 was 200 C and 360 min, respectively, and the
low level (1) for X1 and X2 was 50 C and 30 min,
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levels, a 22 factorial design was conducted to set up four
experiments.
(e) Wet heat degradation: 1 mg/mL of LCZ was heated
under reﬂux at X1 C for X2 min. Two levels were chosen
for X1 and X2. The high level (+1) for X1 and X2 was
100 C and 120 min, respectively, and the low level (1)
for X1 and X2 was 60 C and 30 min, respectively. Since
two variables were considered at two levels, a 22 factorial
design was conducted to set up four experiments.
(f) Photolytic degradation: LCZ powder was spread as a
thin ﬁlm on petri plate and exposed to direct sunlight
for 48 h. A control in dark was also run.
2.4. Chromatographic analysis of stressed samples
Each of the stressed sample obtained was diluted with the mobile
phase to get a ﬁnal concentration of 10 lg/mL, 20 lLof the resulting
solution was injected on HiQsil C18HS (250 mm · 4.6 mm i.d.,
5 lm) at 1 mL/min and the eluent was monitored at 296 nm. The
resulting chromatograms were studied for the appearance of second-
ary peaks and the%reduction in the area of drug peakwith reference
to standard LCZ solution (10 lg/mL). The% reduction in peak area
was considered as % degradation.
2.5. Multiple regression analysis and selection of optimum
conditions
Taking the % degradation as the dependent variable (Y), the
results obtained for each type of forced degradation was sub-
jected to multiple regression analysis to generate the following
type of equation:
Y ¼ b0 þ b1X1 þ b2X2 þ b3X3 þ b12X1X2 þ b13X1X3
þ b23X2X3 þ b123X1X2X3
where b0 is the intercept, b1, b2 and b3, b12, b23, b12 and b123 as
regression coefﬁcients for the variables and interaction be-
tween the variables.
Yates analysis was performed to retain only the signiﬁcant
coefﬁcients. Thereafter, surface response curves were drawn to
characterize the value of variables X1, X2 and X3 required for
adequate 10% degradation. Transformed values of variables
were used to simplify the calculation. The actual values were
obtained by using formula:
Transformed value ¼ X the average of levels
one half the difference of the levels
Finally, degradation experiments were performed using theo-
retical indicated values and degradation samples chromato-
graphed to conﬁrm whether the experimental % degradation
matched with the calculated one.
2.6. Calibration curve
One hundred milligrams of LCZ was accurately weighed and
transferred into 100 mL volumetric ﬂask and the volume was
made up to the mark with methanol. The resulting solution
(1 mg/mL) was diluted with the mobile phase to get concentra-
tion in the range of 2–14 lg/mL and each solution was subjected
to chromatographic analysis in triplicate. The peak areas wereplotted on x-axis and the respective concentrations on y-axis.
Further, the linear regression was performed to generate least
square line and regression equation of type y= ax+ b.
2.7. Analysis of cream formulation
An appropriate portion of 1 g of LuliﬁnTM was weighed and
transferred into a 100 mL beaker using weight by transfer
method. Further, 20 mL of methanol was added and the mix-
ture was heated on a water bath with occasional agitation, till
the cream base gets melted. The melted mixture was trans-
ferred to 100 mL volumetric ﬂask, maintained in water bath
at temperature about 40 C. Further, 5 mL of methanol was
added to the same beaker and the washings were transferred
into the volumetric ﬂask. Finally the volume was adjusted to
the mark with methanol. The mixture was ﬁltered immediately
with Whatman ﬁlter paper no. 1 to suction ﬂask by applying
vacuum. Suitable aliquots were removed and diluted with the
mobile phase to get ﬁnal concentration of 10 lg/mL and sub-
jected to chromatographic analysis. The drug peak area was
referred to the regression equation to get the sample concen-
tration and % nominal label claimed.
2.8. Method validation
The method was validated as per the ICH guideline Q 2 (R1)
(ICH, 2005). To evaluate the accuracy and precision, laboratory
cream samples were prepared by spiking the cream base portions
with appropriate known amounts of LCZ to reach concentrations
of 80%, 100% and 120%of the expected amount of the analyte in
real samples. The resulting mixtures were analyzed in triplicate
over three days. The% recovery of added drug and%RSD were
takenasmeasures of the accuracy andprecision, respectively.Also,
the results obtainedwere subjected to one-way analysis of variance
and within-day mean square compared to between-day mean
square by F-test. Further, the quantity added was plotted against
quantity found and the slope and intercept of the resulting straight
line was obtained. A slope of 1 and intercept of 0 were taken as
indication of linearity of the method in the range of 80–120%.3. Results and discussion
3.1. Multiple regression analysis and selection of optimum
conditions
The forced degradation experiments set-up on the basis of fac-
torial design were performed and the resulting samples were
analyzed by LC. No degradation in drug peak area was ob-
served in case of wet heat and dry heat conditions. Substantial
degradation was observed in acidic, alkaline, oxidative and
photolytic conditions (Fig. 1). The experimental conditions
and degradation obtained for all degradation experiments per-
formed as per the factorial design as summarized in Table 1.
Further, when results obtained for each experiments per-
formed under acid, alkali, oxidative degradation were sub-
jected to multiple regression, the following equations resulted:
Y ¼ 17:38þ 7:62X1 þ 6:38X2 þ 8:12X3 þ 0:62X1X2
 0:88X2X3 þ 3:38X1X3
 1:62X1X2X3 ðacidic degradationÞ ð1Þ
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þ 2:5X2X3 þ 0:75X1X3
 0:25X1X2X3 ðalkaline degradationÞ ð2Þ
Y ¼ 49:75þ 97X1 þ 103X2
þ 1X1X2 ðfor oxidative degradationÞ ð3Þ
Yates analysis indicated that under acidic condition,
strength of HCl (X1) and the temperature (X3) were most sig-
niﬁcant factors and for alkaline condition, time of exposure
(X2) and the temperature (X3) were signiﬁcant. Furthermore,
surface response curves were generated for acid and alkali con-
ditions, respectively. For acid condition, the surface response
curve (Fig. 2) was generated by keeping the X2 at a value of
0 and transformed values of X1 and X3 for y-axis value of
10% of degradation were calculated using Eq. (1). Similarly,
the surface response curve was generated for alkali conditionFigure 1 Chromatograms obtained for (A) reference substance, (B) a
(E) photolytic degradation. Chromatographic condition: HiQSil C18H
methanol:water (80:20%, v/v); detection: 296 nm.(Fig. 3) by keeping the X1 at a value of 0 and transformed val-
ues of X2 and X3 for y-axis value of 10% of degradation were
calculated using Eq. (2). Figs. 2 and 3 depict the surface re-
sponse curves, predicting the optimum degradation lines for
10% degradation of LCZ under acid and alkali conditions,
respectively. These lines suggested that for acidic stress, 10%
degradation would result by using 0.15 M HCl and heating
at 80 C for 45 min. When these conditions were adopted in
practice, the resulting degradation was 11%. Also, for alkaline
degradation from surface response curve line, 10% degrada-
tion would result by using 0.05 M NaOH and heating at
65 C for 20 min. These conditions when adopted in practice
13% degradation was achieved.
For oxidative degradation, the rough grids of predicted re-
sponses were determined from Eq. (3) by considering the val-
ues of X1 and X2 from 1 to +1, respectively. From this, it
has been observed that 18.75% degradation can be achieved
when X1 = 0.75 and X2 = 1. The actual values for X1 andcid hydrolysis, (C) alkali hydrolysis, (D) oxidative degradation and
S (250 · 4.6 mm i.d., 5 lm); ﬂow rate: 1 mL/min, mobile phase:
Table 1 Experimental design and their resulting % degradation under various conditions.
Expt. no. 23 Factorial design Expt. no. 22 Factorial design
X1 X2 X3 Acid hydrolysis Alkali hydrolysis X1 X2 Oxidative Wet heat Dry heat
1 1 1 1 0 0 1 1 1 0 No degradation obtained
2 +1 1 1 4 3 2 1 +1 48
3 1 +1 1 10 8 3 +1 1 51
4 +1 +1 1 23 11 4 +1 +1 100
5 1 1 +1 8 19
6 +1 1 +1 32 26
7 1 +1 +1 21 38
8 +1 +1 +1 41 43
Figure 2 Surface response curve of transformed values for 10% acid degradation.
Figure 3 Surface response curve of transformed values for 10% alkali degradation.
S1432 S. Sonawane, P. GideX2 were determined. Thus, when LCZ was kept in 25% H2O2
for 2 h, resulted in 15% degradation. For photolytic condi-
tions about 8% degradation has been obtained.
3.2. Calibration curve and analysis of marketed formulation
When calibration standards in the range of 2–14 lg/mL were
analyzed in triplicate and plot of peak area vs concentrationwas subjected to least square regression. The respective linear
equation was y= 101218.73x13215.42, where x is the con-
centration (lg/mL) and y is the peak area (lV). The correla-
tion coefﬁcient was 0.9997. Student’s t-test was performed to
verify the signiﬁcance of experimental intercept and slope in
the regression equation. According to the results, it was not
signiﬁcantly different from zero and one value, respectively,
for p> 0.05. The analysis of variance was applied to verify
Table 2 Accuracy and precision studies.
Amount added (mg) Amount found (mg) Within mean square Between mean square F
Days
1 2 3
8 7.99 8.08 7.78 0.0065 0.0302 4.60
8.03 7.89 7.83
8.11 8.01 7.94
Mean 8.04 7.99 7.85
% RSD 0.75 1.20 1.04
10 9.89 10.13 9.89 0.0062 0.0170 2.72
10.02 9.99 9.81
9.91 10.01 9.99
Mean 9.94 10.04 9.89
% RSD 0.70 0.75 0.91
12 12.39 12.04 12.24 0.2306 0.1029 4.46
12.43 12.34 12.12
12.72 12.11 12.34
Mean 12.51 12.16 12.23
% RSD 1.43 1.29 0.90
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served that the calculated F (15,319) was greater than the tab-
ulated F (6.61) at a= 0.05, concluded a linear relationship
exists between the peak area and concentration.
When cream formulation was analyzed using developed
method, the results obtained in good agreement with the nom-
inal amount of the drug. The drug content was found to be
100.46%± 1.19 (n= 3) of the label claimed.
3.3. Method validation
The results obtained for accuracy and precision studies are
shown in Table 2. The % recovery close to 100% and the
low values of % RSD suggest an acceptable accuracy and pre-
cision of the method.
Furthermore, the intra- and inter-day results at each level
were subjected to one-way analysis of variance and the F val-
ues for each level were determined as the ratio of between
mean square (BMS) to within mean square (WMS).
(F=BMS/WMS). The obtained values were found to be less
than the tabulated F (2,6) at a= 0.05 (tabulated F va-
lue = 5.14). These indicated that there was no signiﬁcant dif-
ference between intra- and inter-day variability, suggesting
good intermediate precision of the method.
A plot of quantity added to the quantity obtained resulted in
a straight line with the slope of 1.009 and the intercept of 0.98,
encompasses 1 and 0, respectively. This indicated the linearity
of the method in the selected range of 80–120% of the label
claimed.
The chromatograms of blank and placebo solutions showed
no interfering peak at the retention time of the drug indicating
speciﬁcity of the developed method.4. Conclusions
Hence with regard to the method done, it can be concluded that LCZ is susceptible to degradation under acid, alkali, oxida-
tive and photolytic conditions, but stable under wet heat
and dry heat conditions.
 Use of factorial design, expedited the revolution of vari-
ables that are most likely to inﬂuence the extent of deg-
radation. For acid condition, strength of HCl and the
temperature had largest inﬂuence on % degradation of
LCZ. While for alkali condition, time of exposure and
temperature were signiﬁcant. For oxidative degradation,
it has been observed that there is no interaction
between the strength of H2O2 and the time of
exposure.
 The use of surface response curves to identify theoretical
values of variables for optimum degradation was successful,
because when these parameters were put in practice, the %
degradation obtained matched the predicted degradation.
This suggests that factorial design approach can replace
the trial and error approach used to achieve optimum deg-
radation in forced degradation studies.
 Validation experiments proved that the LC conditions used
were able to impart sufﬁcient speciﬁcity and stability-indi-
cating capability to the method. Also, the method had
desired accuracy, precision and linearity.
 Analysis of cream formulation, proved practical range of
the method.
 Thus, factorial design approach was successfully used to
achieve optimum degradation conditions for LCZ and
an accurate, precise and speciﬁc stability-indicating
LC method was developed for the drug in cream
formulation.
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